STRO Stock Overview
Sutro Biopharma, Inc. operates as a clinical-stage oncology company.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sutro Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.35 |
| 52 Week High | US$6.13 |
| 52 Week Low | US$2.01 |
| Beta | 0.98 |
| 1 Month Change | -0.91% |
| 3 Month Change | -7.25% |
| 1 Year Change | -20.33% |
| 3 Year Change | -76.90% |
| 5 Year Change | -57.18% |
| Change since IPO | -71.38% |
Recent News & Updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02
Recent updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Shareholder Returns
| STRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.4% | 0.5% | 2.7% |
| 1Y | -20.3% | 3.4% | 26.0% |
Return vs Industry: STRO underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: STRO underperformed the US Market which returned 25% over the past year.
Price Volatility
| STRO volatility | |
|---|---|
| STRO Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: STRO's share price has been volatile over the past 3 months.
Volatility Over Time: STRO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 302 | Bill Newell | www.sutrobio.com |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Sutro Biopharma, Inc. Fundamentals Summary
| STRO fundamental statistics | |
|---|---|
| Market cap | US$349.95m |
| Earnings (TTM) | -US$106.79m |
| Revenue (TTM) | US$153.73m |
2.3x
P/S Ratio-3.3x
P/E RatioIs STRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STRO income statement (TTM) | |
|---|---|
| Revenue | US$153.73m |
| Cost of Revenue | US$180.43m |
| Gross Profit | -US$26.69m |
| Other Expenses | US$80.10m |
| Earnings | -US$106.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | -17.36% |
| Net Profit Margin | -69.47% |
| Debt/Equity Ratio | 2.7% |
How did STRO perform over the long term?
See historical performance and comparison